Kyowa Kirin Co. Ltd. has identified new solute carrier family 15 member 4 (SLC15A4) inhibitors potentially useful for the treatment of autoimmune disease and lupus nephritis.
Mirador Therapeutics Inc. has entered into an exclusive worldwide license agreement with Kira Pharmaceuticals for KP-301, a long-acting anti-C5a antibody with potential to treat ANCA-associated vasculitis.
Valerio Therapeutics SA has entered into a binding term-sheet with Abivax SA setting out the principal terms of an exclusive worldwide research and development collaboration to identify, design and evaluate next-generation therapeutic candidates for immune-mediated inflammatory diseases.
